Business Wire

Scientist.com Partners with Top Pharma to Launch COMPLI™, a Global Compliance Standard for Human Biosample Acquisition

Del

Scientist.com, the world's leading marketplace for outsourced scientific services, today announced the launch of a global process for the ethical sourcing of human biosamples using its COMPLI™ functionality. Created in partnership with leading pharmaceutical companies, suppliers and biobank organizations such as the ESBB and UKCRC TCC, COMPLI™ introduces a common, comprehensive process and supply agreement supporting access to human biosamples. The goal is to enable biobanks and other well-known human sample suppliers to more easily connect with researchers in the pharmaceutical and biotech industries and academia.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170921005353/en/

“By simplifying and standardizing processes that previously took months, this initiative should shorten the research cycle and increase the pace of research,” stated Dr. Matharoo-Ball, President Elect, European, Middle Eastern and African Society for Biopreservation and BioBanking (ESBB). “We are pleased to support the development of a standard process that allows us all to rapidly utilise correctly consented human biosamples in an ethically compliant manner.”

Human biological samples, such as organs, tissues and genetic material, are increasingly being used in drug research, but until now there has been no common process governing their acquisition. The new COMPLI™ process helps researchers and suppliers adhere to internal and external (often legislative) procurement policies. It also ensures that appropriate donor consents have been obtained, tracked and communicated throughout the supply chain.

“It is still possible today to purchase human biological samples without any oversight whatsoever, putting all parties at considerable risk if samples are used inappropriately,” stated Matt McLoughlin, Senior Director of Compliance at Scientist.com. “The launch of COMPLI™ will significantly reduce the risks associated with using human samples. It will also enable researchers to gain faster access to critical research tools needed to respond to global health emergencies.”

COMPLI™ establishes a rigorous compliance and governance framework that increases visibility, traceability and control for the scientific research community. It is only available through the Scientist.com marketplace.

About Scientist.com

Scientist.com is the world's leading scientific services marketplace. The marketplace simplifies research sourcing, saves time and money and provides access to innovative tools and technologies - while maintaining full compliance with an organization’s procurement policies. Scientist.com operates private marketplaces for most of the world’s major pharmaceutical companies and the US National Institutes of Health (NIH). Visit scientist.com to learn more.

Join Scientist.com on social media: YouTube, LinkedIn, Twitter, Facebook, Google+ and Instagram.

Contact information

Scientist.com
Sean Preci
Director of Communications
858-455-1300 ext. 401
marketing@scientist.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Exclusive Group Adds Mellanox to BigTec Portfolio19.10.2017 08:00Pressemelding

Exclusive Group, the value-added services and technologies (VAST) group, today announced it has struck a major distribution agreement with Mellanox Technologies to add the market-leading vendor’s datacentre interconnect solutions to the global BigTec portfolio. The deal, which sees Mellanox and BigTec team up in 24 countries across EMEA and APAC, brings global expansion opportunities to both parties as well as hundreds of reseller partners, providing the ideal complement to storage and hyper-converged solutions from fellow BigTec vendors including Nutanix and Rubrik. “Mellanox has a unique and comprehensive technology offering that reflects both its commitment to open standards in networking and cloud computing, and its hunger to continually disrupt the datacentre market,” said Martin Bichler, Group Vendor Manager, BigTec. “This is yet another bonus for BigTec specialist resellers and

More Firms Select Duco for Mandatory MiFID II Reconciliation19.10.2017 07:01Pressemelding

Duco, the global provider of self-service data normalization and reconciliation services, today announced that a further three firms will be using Duco Cube, the company’s flagship reconciliation solution, for MiFID II reporting reconciliation. The firms include Redburn, Europe’s largest independent equities broker, and two global banks. Ranith de Silva, Operations Manager at Redburn, said: “MiFID II transaction data needs to undergo a number of enrichment processes between front office capture and the final report, which need to be replicated in the reconciliation process, covering large complex data sets. The quick deployment, flexibility and usability of Duco's self-service application enables us to efficiently build towards this reconciliation process with very little technical support.” Regular reconciliation is a mandatory requirement under MiFID II. The firms w

SIAE MICROELETTRONICA Successfully Tests The SDN Application iVeritas in Telefónica Deutschland’s SDN Live Wireless Network19.10.2017 07:00Pressemelding

SIAE MICROELETTRONICA announces the successful deployment of iVeritas in Telefónica Deutschland's mobile backhaul as part of the TST project. Telefónica Deutschland Transport SDN Trial (TST), is a project whose long-term aim is offering value added services on future 5G network infrastructure in an SDN environment. As part of this project SIAE MICROELETTRONICA, a Telefónica long term supplier of wireless technology, deployed its new SDN application named iVeritas offering multivendor performance analytics and preventive maintenance analysis. iVeritas sits on top of the OpenDaylight transport SDN controller that through an SDN mediator interfaces to existing SNMP microwave links, the selected portion of the network was composed by links from three different vendors. iVeritas collected performance information from the links, correlating the data and presenting them acco

Rimini Street Expands Investment and Operations in Europe18.10.2017 22:00Pressemelding

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the appointment of industry leader Marc Chesover as general manager of Europe, the Middle East and Africa (EMEA). The Company also announced the launch of its French subsidiary, hiring of new staff and opening of its new office in Paris, France. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006654/en/ Rimini Street Expands Investment and Operations in Europe (Photo: Business Wire) Enterprise Software Veteran Leads EMEA Operations Rimini Street’s new general manager, Marc Chesover, will lead the Company’s sales and service delivery operations across EMEA, and the next p

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy18.10.2017 21:43Pressemelding

Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006639/en/ CAR T therapy is a breakthrough in hematologic cancer treatment in which

IFF Launches Re-Imagine…™ Programs to Tap Unmet Consumer Opportunities, Speed Innovation18.10.2017 20:15Pressemelding

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, launched their Re-Imagine programs to accelerate innovation and increase agility to capture unmet opportunities in the changing food and beverage market. Based on a combination of future trends analysis, consumer insights, and a modernized cross-category development process, the programs guide the Company’s research and development efforts to ensure an innovation pipeline that addresses evolving consumer needs and desires. “The Re-Imagine programs area tangible expression of our commitment to advance taste for our customers – and consumers,” said IFF Chairman and CEO Andreas Fibig. “It is another way in which we show how we are dedicated to being our customers’ partner of choice as we progress on our business strategy, imbu

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom